Cover Image

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV

Fuente: Wiley Open Access

Saved in:

Bibliographic Details
Main Authors:	Rong‐Xiang Ng, Raja Iskandar Shah Raja Azwa, Wah‐Kheong Chan
Format:	Artículo Open Access
Published:	Wiley 2025
Subjects:	Alimentary Pharmacology & Therapeutics
Online Access:	Acceder al recurso
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV
by: Juan Macias, et al.
Published: (2024)

Letter: Impact of Nonalcoholic Fatty Liver Disease on the Survival of People Living With HIV—Authors' Reply
by: Juan Macias, et al.
Published: (2025)

Editorial: The Impact of Socioeconomic and Ethnic Factors on Chronic Liver Disease
by: Wah Loong Chan, et al.
Published: (2024)

Diagnosis and non‐invasive assessment of MASLD in type 2 diabetes and obesity
by: Wah‐Kheong Chan, et al.
Published: (2024)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease
by: Qiong Yi, et al.
Published: (2024)

Letter: The Prognostic Role of IGF‐1 in Chronic Liver Disease
by: Muhammad Osama, et al.
Published: (2024)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions. Authors' Reply
by: Ryan Yanzhe Lim, et al.
Published: (2026)

Editorial: Targeting Urgency in IBD —A Historical Divide
by: Daniele Noviello, et al.
Published: (2025)

Systematic Review: Incidence of Liver‐Related Events in People Living With Hepatitis Delta Virus
by: Laura E. Telep, et al.
Published: (2025)

Letter: Zinc and Selenium—Potential Biomarkers for Chronic Liver Disease? Authors' Reply
by: Nina Dominik, et al.
Published: (2024)

Letter: Combination Therapies With Vitamin E for Metabolic Dysfunction‐Associated Steatotic Liver Disease
by: Stergios A. Polyzos, et al.
Published: (2024)

Letter: Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease‐Related Liver Cancer—Results From the Global Burden of Disease Study 2021
by: Chunlong Liu, et al.
Published: (2025)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’
by: Sai Kiran Kuchana, et al.
Published: (2026)

Letter: Liver Transplantation Outcomes for Alcohol‐Associated Liver Disease—Commentary on an Individual Patient Data Meta‐Analysis and Future Research Directions
by: Xinglin Li, et al.
Published: (2026)

Letter: The Essential Role of Social Workers in Reducing Socioeconomic Disparities in Chronic Liver Disease—Author's Reply
by: Eunice Yewon Lee, et al.
Published: (2024)

Letter on ‘Inherited Genetic Risk of Liver Fibrosis in Lean Versus Nonlean Metabolic Dysfunction‐Associated Steatotic Liver Disease ( MASLD )’; Authors’ reply
by: Kaleb Tesfai, et al.
Published: (2026)

Letter on: ‘Impact of Frailty on the Prognosis of Patients With Liver Cirrhosis Undergoing Insertion of a TIPS ’. Authors' Reply
by: Christian Labenz, et al.
Published: (2026)

Waitlist and Post‐Transplant Outcomes in Liver Transplantation for Alcohol‐Associated Liver Disease: An Individual Patient Data Meta‐Analysis
by: Glenn Jun Kit Ho, et al.
Published: (2025)

Letter on ‘Long‐Term Dynamic Changes of Alanine Aminotransferase Levels Are Associated With Liver‐Related Events in Nucleos(t)ide Analogue‐Treated Chronic Hepatitis B Patients in China’—Authors' Reply
by: Ning Yu, et al.
Published: (2025)

Letter: From Regional Diagnostic Thresholds to Phenotype‐Guided Management in Asian Reflux Disease. Authors' Reply
by: Walter W. Chan, et al.
Published: (2026)

Editorial: Patient Reported Outcomes Provide Insight Into Disease Severity for People Living With Primary Sclerosing Cholangitis
by: Aisha Alawi, et al.
Published: (2025)

Letter: Safety and Tolerability of Injectable Extended Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease
by: Xing Bai, et al.
Published: (2025)

Letter: Comparison of the Efficacy of Adjuvant PD‐1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) Related HCC Versus Other Aetiologies
by: Jia‐Yong Su, et al.
Published: (2025)

Editorial: Liver and Non‐Liver Outcomes Between Different Subtypes of Steatotic Liver Disease
by: Jee‐Fu Huang, et al.
Published: (2026)

Letter: Amino Acid Imbalance Is an Independent Factor for Mortality in Patients With Liver Cirrhosis
by: Zhanbo Qu
Published: (2026)

Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
by: Luis Antonio Díaz, et al.
Published: (2025)

Letter: Resmetirom for treatment of MASH with children and adolescents
by: Yong‐Hai Zhou, et al.
Published: (2024)

Differential Characteristics and Survival Outcomes of Patients With Cirrhosis According to Underlying Liver Aetiology
by: Yu Shi, et al.
Published: (2025)

Alcohol–Related Liver Disease, Followed by Metabolic Dysfunction–Associated Steatotic Liver Disease, Emerges as the Fastest‐Growing Aetiologies for Primary Liver Cancer in the United States
by: Pojsakorn Danpanichkul, et al.
Published: (2025)

Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk
by: Julia Karady, et al.
Published: (2024)

Letter: Enhancing Risk‐Adapted Colorectal Cancer Screening for People With Diabetes—Authors' Reply
by: Teresa Seum, et al.
Published: (2025)

Letter: Bowel Preparation Quality in Patients With Crohn's Disease
by: Tamar Schildkraut, et al.
Published: (2024)

Impact of GLP‐1 Receptor Agonists on Alcohol‐Related Liver Disease Development and Progression in Alcohol Use Disorder
by: Chia‐Chih Kuo, et al.
Published: (2025)

Letter: Crohn's Disease or Comorbidity? Reassessing Opioid Prescribing Patterns
by: Kuan‐Ju Lin, et al.
Published: (2025)

Letter: Supporting the Role of Enzyme Therapy in Management of Coeliac Disease
by: Finlay Macrae
Published: (2025)

Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol
by: Karen Cheuk‐Ying Ho, et al.
Published: (2025)

Letter: Comparing the Efficacy of Adjuvant PD–1 Inhibitor After Curative Resection for Metabolic Dysfunction‐Associated Steatotic Liver Disease Related HCC Versus Other Aetiologies—Authors' Reply
by: Isabella Lurje, et al.
Published: (2025)

Letter: Beyond Survival Benefit in CHANCE2311—Important Considerations in the Interpretation of TACE Combined With Immunotherapy in Advanced HCC
by: Yinghan Chen, et al.
Published: (2026)

Editorial: Steatotic Liver Diseases Emerge as Rapidly Growing Drivers of Primary Liver Cancer in the United States
by: Kelly Torosian, et al.
Published: (2025)

Letter: Inflammatory Potential of the Diet and Risk of Crohn's Disease and Ulcerative Colitis
by: Zhidong Zhou, et al.
Published: (2025)